MAIDSTONE

HEART OF KENT METAL DETECTING RALLY 2022 KICKS OFF WITH MINELAB

Retrieved on: 
Tuesday, August 23, 2022
Blog, Camping, MAIDSTONE, Snow, Technology, Multimedia, Global, Bed, Detectorists, Magnetism, Industry, Medical imaging, Online shopping

LENHAM, MAIDSTONE, England, Aug. 23, 2022 /PRNewswire/ -- In one of the UK's premiere detecting festivals, Minelab will be joining Joan Allen Events at the Heart of Kent Metal Detecting Rally Aug. 26 through 29, 2022. The four-day event spans Friday through Monday and will give detectorists a wonderful opportunity to explore the expansive field block properties. Attendees can visit the Minelab booth and test beds to experience some of the most innovative detecting technology in the industry first-hand and learn from international Minelab experts.

Key Points: 
  • Join Minelab Metal Detectors at their test beds at the UK metal detecting rally Aug. 26 29.
  • LENHAM, MAIDSTONE,England, Aug. 23, 2022 /PRNewswire/ -- In one of the UK's premiere detecting festivals, Minelab will be joining Joan Allen Events at the Heart of Kent Metal Detecting Rally Aug. 26 through 29, 2022.
  • Attendees can visit the Minelab booth and test beds to experience some of the most innovative detecting technology in the industry first-hand and learn from international Minelab experts.
  • "We are so proud to be a part of the Joan Allen Heart of Kent Detecting Rally this year and are excited for a weekend full of detecting activities.

HEART OF KENT METAL DETECTING RALLY 2022 KICKS OFF WITH MINELAB

Retrieved on: 
Tuesday, August 23, 2022
Blog, Camping, MAIDSTONE, Snow, Technology, Global, Bed, Detectorists, Magnetism, Industry, Nightclub

LENHAM, MAIDSTONE, England, Aug. 23, 2022 /PRNewswire/ -- In one of the UK's premiere detecting festivals, Minelab will be joining Joan Allen Events at the Heart of Kent Metal Detecting Rally Aug. 26 through 29, 2022. The four-day event spans Friday through Monday and will give detectorists a wonderful opportunity to explore the expansive field block properties. Attendees can visit the Minelab booth and test beds to experience some of the most innovative detecting technology in the industry first-hand and learn from international Minelab experts.

Key Points: 
  • Join Minelab Metal Detectors at their test beds at the UK metal detecting rally Aug. 26 29.
  • LENHAM, MAIDSTONE,England, Aug. 23, 2022 /PRNewswire/ -- In one of the UK's premiere detecting festivals, Minelab will be joining Joan Allen Events at the Heart of Kent Metal Detecting Rally Aug. 26 through 29, 2022.
  • Attendees can visit the Minelab booth and test beds to experience some of the most innovative detecting technology in the industry first-hand and learn from international Minelab experts.
  • "We are so proud to be a part of the Joan Allen Heart of Kent Detecting Rally this year and are excited for a weekend full of detecting activities.

66% of diagnostic biopsies for common skin cancer can be avoided using Michelson Diagnostics' VivoSight OCT laser scanner

Retrieved on: 
Monday, August 1, 2022
MRI, Biopsy, Diagnosis, University, Skin, United Kingdom, The Lancet, Dermatology, BCC, University College Maastricht, Hospital, CEO, Squamous cell carcinoma, Skin cancer, Research, OCT, Incidence, Basal-cell carcinoma, NHS, Scar, Cancer, Recurrence, Optical coherence tomography, Ageing, Technology, Lancet, Patient, Pain, MAIDSTONE, Population, Medical imaging, Dietary supplement

It is the most common form of skin cancer that is rapidly increasing, with it affecting one in five people in the white population in their lifetime3.

Key Points: 
  • It is the most common form of skin cancer that is rapidly increasing, with it affecting one in five people in the white population in their lifetime3.
  • OCT is an advanced laser scanning tool which enables clinicians to non-invasively view below the surface of the skin at much higher resolutions than is possible with other technologies such as MRI or X-ray.
  • Michelson Diagnostics' VivoSight machine is already the world's leading scanner for the skin and has revolutionised how dermatologists conduct their treatment plans.
  • The study has proved that using the OCT can dramatically improve patient's physical care and treatment time.

66% of diagnostic biopsies for common skin cancer can be avoided using Michelson Diagnostics' VivoSight OCT laser scanner

Retrieved on: 
Monday, August 1, 2022
MRI, Biopsy, Diagnosis, University, Skin, United Kingdom, The Lancet, Dermatology, BCC, University College Maastricht, Hospital, CEO, Squamous cell carcinoma, Skin cancer, Research, OCT, Incidence, Basal-cell carcinoma, NHS, Scar, Cancer, Recurrence, Optical coherence tomography, Ageing, Technology, Lancet, Patient, Pain, MAIDSTONE, Population, Medical imaging, Dietary supplement

It is the most common form of skin cancer that is rapidly increasing, with it affecting one in five people in the white population in their lifetime3.

Key Points: 
  • It is the most common form of skin cancer that is rapidly increasing, with it affecting one in five people in the white population in their lifetime3.
  • OCT is an advanced laser scanning tool which enables clinicians to non-invasively view below the surface of the skin at much higher resolutions than is possible with other technologies such as MRI or X-ray.
  • Michelson Diagnostics' VivoSight machine is already the world's leading scanner for the skin and has revolutionised how dermatologists conduct their treatment plans.
  • The study has proved that using the OCT can dramatically improve patient's physical care and treatment time.

Bedfont Scientific Ltd receives FDA clearance for NObreath® FeNO monitor

Retrieved on: 
Monday, January 31, 2022
Online, Diagnosis, Patient, Online and offline, ATS, Food, MAIDSTONE, Critical Care Medicine (journal), Internet, National Centre for Disease Control, Healthcare Professionals for Healthcare Reform, Bedfont, Nitric acid, Inflammation, Asthma, ERS, Center, American Journal of Respiratory and Critical Care Medicine, CDC, Taylor & Francis, Eosinophilic, Allergy, Nitric oxide, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Medical device, Explosive, Dietary supplement

MAIDSTONE, England, Jan. 31, 2022 /PRNewswire/ -- UK, med-tech company, Bedfont Scientific Ltd., is celebrating a brighter 2022 as the U.S. Food and Drug Administration (FDA) cleared its NObreath FeNO monitor for use in monitoring airway inflammation.

Key Points: 
  • MAIDSTONE, England, Jan. 31, 2022 /PRNewswire/ -- UK, med-tech company, Bedfont Scientific Ltd., is celebrating a brighter 2022 as the U.S. Food and Drug Administration (FDA) cleared its NObreath FeNO monitor for use in monitoring airway inflammation.
  • The NObreath, which conforms to ATS and ERS guidelines1, is a portable, non-invasive device for the measurement of Fractional Exhaled Nitric Oxide (FeNO) in human breath.
  • The NObreath works by measuring FeNO through breath analysis, making the process quick, simple, and non-invasive for both the Healthcare Professional and the patient.
  • We are one step closer to achieving our purpose; to make FeNO monitoring lower cost and therefore more accessible globally.

Bedfont Scientific Ltd receives FDA clearance for NObreath® FeNO monitor

Retrieved on: 
Monday, January 31, 2022
Online, Diagnosis, Patient, Online and offline, ATS, Food, MAIDSTONE, Critical Care Medicine (journal), Internet, National Centre for Disease Control, Healthcare Professionals for Healthcare Reform, Bedfont, Nitric acid, Inflammation, Asthma, ERS, Center, American Journal of Respiratory and Critical Care Medicine, CDC, Taylor & Francis, Eosinophilic, Allergy, Nitric oxide, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Multimedia, Medical device, Explosive

MAIDSTONE, England, Jan. 31, 2022 /PRNewswire/ -- UK, med-tech company, Bedfont Scientific Ltd., is celebrating a brighter 2022 as the U.S. Food and Drug Administration (FDA) cleared its NObreath FeNO monitor for use in monitoring airway inflammation.

Key Points: 
  • MAIDSTONE, England, Jan. 31, 2022 /PRNewswire/ -- UK, med-tech company, Bedfont Scientific Ltd., is celebrating a brighter 2022 as the U.S. Food and Drug Administration (FDA) cleared its NObreath FeNO monitor for use in monitoring airway inflammation.
  • The NObreath, which conforms to ATS and ERS guidelines1, is a portable, non-invasive device for the measurement of Fractional Exhaled Nitric Oxide (FeNO) in human breath.
  • The NObreath works by measuring FeNO through breath analysis, making the process quick, simple, and non-invasive for both the Healthcare Professional and the patient.
  • We are one step closer to achieving our purpose; to make FeNO monitoring lower cost and therefore more accessible globally.